EP Lab

This channel includes news and new technology innovations for cardiac electrophysiology (EP) systems, techniques and devices using in EP labs. This includes implantable EP devices, pacemakers, implantable cardioverter defibrillators (ICD), cardiac resychronization therapy (CRT), ablation technologies, left atrial appendage (LAA) occlusion, atrial fibrilation (AF) and Holter monitors.

Technology | Patient Monitors

May 16, 2018 — Itamar Medical Ltd. announced the launch of SleePath, the first integrated e-health sleep apnea care ...

Home May 16, 2018
Home
News | Implantable Cardioverter Defibrillator (ICD)

May 16, 2018 — Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful ...

Home May 16, 2018
Home
News | Atrial Fibrillation

May 15, 2018 — A new study is the first to report a relationship between post-traumatic stress disorder (PTSD) and new ...

Home May 15, 2018
Home
News | Atrial Fibrillation

May 15, 2018 — According to new research, smoking marijuana may not be associated with an increased risk of ventricular ...

Home May 15, 2018
Home
News | Atrial Fibrillation

May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception and ...

Home May 15, 2018
Home
News | Atrial Fibrillation

May 11, 2018 — A new study finds that integrating two separate clinical risk score models more accurately helps ...

Home May 11, 2018
Home
News | Vascular Closure Devices

May 10, 2018 — Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical ...

Home May 10, 2018
Home
News

May 10, 2018 — Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of ...

Home May 10, 2018
Home
News | ECG Monitoring Services

May 9, 2018 – Medicalgorithmics S.A. will present the results of a large study evaluating online versus offline electroc ...

Home May 09, 2018
Home
Technology | Implantable Cardiac Monitor (ICM)

 May 9, 2018 — The U.S. Food and Drug Administration (FDA) said it recently granted market clearance for Angel Medical ...

Home May 09, 2018
Home
Videos | Stroke

A new clinical trial at The Ohio State University Wexner Medical Center is examining an implanted device that uses vagus ...

Home May 09, 2018
Home
News | Stroke

May 9, 2018 — Stroke rehabilitation specialists at the The Ohio State University Wexner Medical Center are among the ...

Home May 09, 2018
Home
Technology

May 8, 2018 — Biosense Webster Inc. announced its Carto Vizigo Bi-directional Guiding Sheath is now available in the ...

Home May 08, 2018
Home
News | ECG Monitoring Services

May 8, 2018 — Bardy Diagnostics Inc. (BardyDx) announced that the American Heart Journal has published the results of a ...

Home May 08, 2018
Home
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Feature | Antiplatelet and Anticoagulation Therapies

May 7, 2018 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first ...

Home May 07, 2018
Home
Subscribe Now